Bibliography
- Ichikawa J, Li Z, Dai J, Atypical antipsychotic drugs, quetiapine, iloperidone and melperidone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956:349-57
- Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-14
- Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychoharmacol Biol Psychiatry 2002;26:553-60
- Potkin SG, Litman RE, Torres R, Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28:S4-11
- Kay ST, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;12:261-76
- Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9
- Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No. ADM 76-338). Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD: USA; 1976. p. 218-22
- Cutler AJ, Kalali AH, Weiden PJ, Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(Suppl 1):S20-8
- Cutler AJ, Bishop JR. An update on the investigational antipsychotic iloperidone: an expert interview with Andrew J. Cutler, MD. Medscape Psychiatry & Mental Health. 2008. Available from: http://medscape.com/viewarticle/571878 [Last accessed 21 September 2009]
- Kane JM, Lauriello J, Laska E, Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(Suppl 1):S29-35
- Weiden PJ, Cutler AJ, Polymeropoulos MH, Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(Suppl 1):S12-19
- Chouinard G, Ross-Chouinard A, Annable L, The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233
- Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6
- Volpi S, Potkin SG, Malhotra AK, Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70:801-19
- Volpi S, Heaton C, Mack K, Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009;14:1024-31
- Yan J. FDA reverses earlier decision, approves schizophrenia drug. Psychiatr News 2009;44:2
- Hill CL, Phadke D, Boyce KM. Four-week iloperidone depot injectable: safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder [Poster NR4-022]. American Psychiatric Association 2008 Annual Meeting; 3 – 8 May 2008; Washington, DC, USA. In: New Research Abstracts. Arlington, VA: American Psychiatric Association, 2008. p. 169-70